La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Autolus Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Autolus Therapeutics..

Autolus Therapeutics (NASDAQ:AUTL) Azioni, Catena delle Opzioni

AUTOLUS THERAPEUTICS PLC

Autolus Therapeutics

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics PLC

Austal Ltd

UBS analyst Timothy Chiodo maintains Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) with a Neutral and lowers the price target from $125 to $110.

News

Price Target

Analyst Ratings

SHOP

UBS Maintains Neutral on Shopify, Lowers Price Target to $110

UBS analyst Kunal Madhukar maintains RealReal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>) with a Neutral and raises the price target from $6 to $7.

REAL

UBS Maintains Neutral on RealReal, Raises Price Target to $7

UBS analyst A.J. Rice maintains Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) with a Sell and raises the price target from $4.5 to $5.

AVAH

UBS Maintains Sell on Aveanna Healthcare Hldgs, Raises Price Target to $5

CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) today announced it has reached a tentative agreement with the Brotherhood of Locomotive Engineers and Trainmen (BLET) on a new five-year single-system agreement covering approximately 3,400 locomotive engineers.
This is the first agreement reached by a Class I freight railroad with BLET, and it continues CSX's industry-leading transformational approach to collective bargaining in the rail industry.

Contracts

CSX Announces It Has Reached A Tentative Agreement With The Brotherhood Of Locomotive Engineers And Trainmen On A New 5- year Single-System Agreement Covering ~3,400 Locomotive Engineers

UBS analyst Kunal Madhukar maintains Cars.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) with a Neutral and lowers the price target from $13 to $12.

CARS

UBS Maintains Neutral on Cars.com, Lowers Price Target to $12

Chicago Rivet &amp; Machine (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVR#AMEX">CVR</a>) reported quarterly earnings of $0.42 per share. This is a 158.33 percent increase over losses of $(0.72) per share from the same period last year. The company reported $7.25 million in sales this quarter. This is a 7.74 percent decrease over sales of $7.85 million the same period last year.

Earnings

Chicago Rivet & Machine Q1 EPS $0.42 Up From $(0.72) YoY, Sales $7.25M Down From $7.85M YoY

UBS analyst Batya Levi maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Buy and lowers the price target from $41 to $38.

UBS Maintains Buy on Warner Music Gr, Lowers Price Target to $38

Offerings

Alliant Energy Files For Common Stock Offering Of Up To $1.3B

UBS analyst Kunal Madhukar maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Neutral and raises the price target from $29 to $33.

CARG

UBS Maintains Neutral on CarGurus, Raises Price Target to $33

UBS analyst Stephen Ju maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Neutral and raises the price target from $12 to $14.

LYFT

UBS Maintains Neutral on Lyft, Raises Price Target to $14

AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) has outperformed the market over the past 20 years by 9.0% on an annualized basis producing an average annual return of 17.16%. Currently, AZZ has a market capitalization of $2.69 billion. 
Buying $100 In AZZ: If an investor had bought $100 of AZZ stock 20 years ago, it would be worth $2,384.10 today based on a price of $90.00 for AZZ at the time of writing.
<h3>AZZ's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746826227_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In AZZ 20 Years Ago Would Be Worth This Much Today

UBS maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Buy and raises the price target from $13 to $16.

UBS Maintains Buy on CNH Industrial, Raises Price Target to $16

~ Ended First Quarter with $759.0 Million in Cash/Investments ~
~ Operations Consumed Just $9.7 million of Cash Despite $10.9 Million in Primarily Legacy Legal Fees ~
~ Diversified into FinTech and Financial Services with Launch of Truth.Fi ~
~ Preparing to Launch Truth+ Subscription Service ~
~ Eyeing Further Expansion through Mergers/Acquisitions ~
SARASOTA, Fla., May 09, 2025 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: <a href="https://www.benzinga.com/stock/djt#Nasdaq,%20NYSE%20Texas">DJT</a>) ("Trump Media" or the "Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, is announcing financial results for the fiscal quarter ending on March 31, 2025, and is filing its 10-Q with the Securities and Exchange Commission (the "SEC") today.
In the first quarter Trump Media maintained a strong balance sheet, ending the quarter with $759.0 million of cash, cash equivalents, and short-term investments. The Company believes this amount of liquidity, in conjunction with Trump Media's low operating costs and low cash burn rate, will fully enable it to pursue all its expansion plans, including enhancing its existing platforms, diversifying into fintech and financial services, and pursuing potential mergers and acquisitions.
In the first quarter, Trump Media pursued its mission with the following actions:
<ul>
<li>Introduced the Truth.Fi fintech and financial services brand.</li>
<li>Partnered with Crypto.com and Yorkville America Digital to develop a slate of customized exchange-traded funds and products (collectively, "ETFs") with America-First themes incorporating both cryptocurrencies and traditional securities.</li>
<li>Partnered with Index Technologies Group and Yorkville America Equities to develop a slate of customized separately managed accounts ("SMAs") with America-First themes.</li>
<li>Adopted a financial services and fintech strategy that includes investing up to $250 million, to be custodied by Charles Schwab, in assets including Truth.Fi's own financial products, cryptocurrencies, and other securities.</li>
<li>Secured payment processing capabilities for the Truth Social and Truth+ platforms.</li>
<li>Debuted on the New York Stock Exchange in Texas, complementing the Company's listing on the Nasdaq.</li>
<li>Launched an app to stream Truth+ content on Roku television sets alongside numerous other connected TV brands. &nbsp;</li>
</ul>
Trump Media also recently obtained shareholder approval for the Company's reincorporation in Florida, which became effective on April 30.
Described in Trump Media's recent <a href="https://www.globenewswire.com/Tracker?data=5XFqGlXobISEJRIH1paPLUN5MbF2BpeNEInquv7bp6fT7yLPxTRmKjtV89GbZhG2XDMzyTUT2i2VQaEGWZd-2rT9cgZ662MakblsAQtgu6t4PE8lEL7_vnLHcOS4739BHWXVhn9GWab_raN9BytX0g==">letter to shareholders</a>, the Company's ambitious growth strategy envisions expanding all its current operations and moving into new realms, with Trump Media eventually evolving into a holding company for prime assets spanning numerous industries. The Company's plans include:
<ul>
<li>Offering premium features on the Truth Social platform to subscribers of its Truth+ streaming service including an edit button, scheduled Truths, save drafts, expanded character counts, the ability to upload longer videos, and giving all Truth+ subscribers automatic verification on Truth Social with a red check badge and a Truth+ badge.</li>
<li>Monetizing the Truth+ platform, including through advertising and a subscription package with premium content, while continuing its efforts to secure new programming.</li>
<li>As part of a rewards program, introducing a utility token within a Truth digital wallet that can initially be used to pay for Truth+ subscription costs, and later be applied to other products and services in the Truth ecosphere.</li>
<li>Completing the launch this year of the Truth.Fi ETFs and SMAs.&nbsp;</li>
<li>Further diversifying into new sectors by forming partnerships with great companies that align with the Company's mission, and acquiring crown jewel assets through mergers and acquisitions with top-quality companies. &nbsp;</li>
</ul>
Trump Media Chairman and CEO Devin Nunes said, "As we launched our diversification strategy last quarter, we developed unique financial products to meet the demand for non-woke funds that invest in superior American companies. We anticipate that this offering will just be the initial step in a wider expansion into new realms and industries, which will occur as we enhance both Truth Social and Truth+, including our plan to introduce a Truth+ subscription package with premium content. We are now taking every possible step to position the Company to expand robustly throughout the America-First economy."
The Company had a low operating cash outflow of $9.7 million including combined interest income and revenues of $8.8 million for the quarter. Trump Media incurred $10.9 million in legal fees, including costs related to the Company's March 2024 merger with a special purpose acquisition company—one of the longest SPAC mergers in history. The fees include those incurred in litigation aiming to recoup merger-related damages from those individuals and entities that the Company alleges caused the delay of the SPAC through their wrongful acts, as well as expenses related to the Company's reincorporation from Delaware to Florida.&nbsp;Additionally, Trump Media had net losses including $19.6 million in non-cash expenses for stock-based compensation, depreciation and amortization, resulting in a GAAP net loss of $31.7 million and a GAAP operating loss of $39.5 million.
In the first quarter, the Company continued to focus on building out its ecosystem, improving its existing platforms, and diversifying into financial services. Trump Media believes its robust and uncancellable infrastructure, expanding range of services, and strong balance sheet that includes $759.0 million of cash and investments strongly positions the Company to begin implementing monetization plans on its platforms, fully launch Truth.Fi financial products, and continue pursuing new assets and/or partnerships, including via potential mergers and acquisitions.

UPDATE: Trump Media Reports Q1 2025 Results; Says Ended Q1 With $759M In Cash/Investments; Preparing To Launch Truth+ Subscription Service; Eyeing Further Expansion Through Mergers/Acquisitions

Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) reported quarterly losses of $(0.14) per share. This is a 96.12 percent increase over losses of $(3.61) per share from the same period last year. The company reported $821.20 thousand in sales this quarter. This is a 6.58 percent increase over sales of $770.50 thousand the same period last year.

Trump Media & Technology Q1 EPS $(0.14) Up From $(3.61) YoY, Sales $821.20K Up From $770.50K YoY

RSLS

ReShape Lifesciences Files For Mixed Shelf Offering Of Up To $50M

Vince Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) ("VNCE" or the "Company"), a global contemporary retailer, today announced that on May 6, 2025, the Company received a written notice (the "Notice") from the New York Stock Exchange ("NYSE") that the Company did not presently satisfy NYSE's continued listing standards under Section 802.01B of NYSE Listed Company Manual (the "Manual"), which requires the Company's 30-trading day average market capitalization to be at least $50 million and the Company's stockholders' equity to be at least $50 million. As set forth in the Notice, as of May 5, 2025, the Company's 30-trading day average market capitalization was approximately $22.6 million and the Company's last reported stockholders' equity, as of February 1, 2025, was approximately $41.8 million.

VNCE

Vince Holding Receives Continued Listing Standard Notice From The NYSE

BURU

Nuburu Files For Mixed Shelf Offering Of Up To $100M

UBS analyst Kevin Caliendo maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Buy and raises the price target from $14 to $15.

UBS Maintains Buy on Evolent Health, Raises Price Target to $15

Whitestone REIT Files For Mixed Shelf Offering Of Up To $750M

UBS analyst Taylor McGinnis maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Neutral and lowers the price target from $38 to $33.

UBS Maintains Neutral on RingCentral, Lowers Price Target to $33

Press Releases

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

General

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Comments

Autolus Therapeutics

Autolus Therapeutics (AUTL) Opzioni

Autolus Therapeutics (NASDAQ:AUTL) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO